At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 152 enrolled
Drug / intervention
Atezolizumab +1 moredrug
Likely dose
Atezolizumab 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
In Brief
A Phase 3 clinical trial evaluating Atezolizumab and Bevacizumab for Carcinoma, Hepatocellular. Completed, enrolled 152 participants across 21 sites.
Detailed Summary
This is a Phase IIIb, one arm, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab + bevacizumab in patients with unresectable HCC who have received no prior systemic treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Hepatocellular
CountriesItaly
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartAug 2020
Primary CompletionAug 2024
TodayJul 2026
First PostedJul 27, 2020
Enrollment StartAug 25, 2020
Primary CompletionAug 13, 2024
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 5.9 years ago
Interventions
Atezolizumabdrug
Atezolizumab 1200 mg IV infusion q3w
Bevacizumabdrug
Bevacizumab 15 mg/kg IV Q3W